{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:10:17Z","timestamp":1790802617921,"version":"4.1.0"},"reference-count":46,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2019,10,22]]},"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study assessed the psychometric properties of the fatigue numeric rating scale (NRS) and sought to establish values for clinically meaningful change (responder definition).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using disease-specific clinician-reported and patient-reported data from two randomised clinical trials of patients with psoriatic arthritis (PsA), the fatigue NRS was evaluated for test\u2013retest reliability, construct validity and responsiveness. A responder definition was also explored using anchor-based and distribution-based methods.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Test\u2013retest reliability analyses supported the reproducibility of the fatigue NRS in patients with PsA (intraclass correlation coefficient=0.829). Mean (SD) values at baseline and week 2 were 5.7 (2.2) and 5.7 (2.4), respectively. Supporting construct validity of the fatigue NRS, moderate-to-large correlations with other assessments measuring similar concepts as measured by Sackett\u2019s conventions were demonstrated. Fatigue severity was reduced when the underlying disease activity was improved and reductions remained consistent at week 12 and 24. A 3-point improvement was identified as being optimal for demonstrating a level of clinically meaningful improvement in fatigue NRS after 12\u201324 weeks of treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Fatigue NRS is a valid and responsive patient-reported outcome instrument for use in patients with PsA. The established psychometric properties from this study support the use of fatigue NRS in clinical trials and in routine clinical practice. Robust validation of reliability for use in routine clinical practice in treating patients with active PsA in less active disease states and other more diverse ethnic groups is needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2019-000928","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T05:55:17Z","timestamp":1578462917000},"page":"e000928","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":52,"title":["Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis"],"prefix":"10.1136","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct01695239","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02349295","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01695239","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02349295","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna","family":"Gladman","sequence":"first","affiliation":[{"name":"Medicine\/Rheumatology, Krembil Research Institute, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nash","sequence":"additional","affiliation":[{"name":"Department of Medicine, Griffith University, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Goto","sequence":"additional","affiliation":[{"name":"Osaka City University Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A","family":"Birt","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yen","family":"Lin","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8644-8567","authenticated-orcid":false,"given":"Ana-Maria","family":"Orbai","sequence":"additional","affiliation":[{"name":"Medicine Rheumatology, Johns Hopkisn University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore K","family":"Kvien","sequence":"additional","affiliation":[{"name":"Rheumatology, Diak Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,1,7]]},"reference":[{"key":"2025090312465902000_6.1.e000928.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.05.001"},{"key":"2025090312465902000_6.1.e000928.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2025090312465902000_6.1.e000928.3","first-page":"34","article-title":"Fatigue in psoriasis with arthritis","volume":"9","author":"Carneiro","year":"2011","journal-title":"Skinmed"},{"key":"2025090312465902000_6.1.e000928.4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jbspin.2015.07.017","article-title":"Fatigue in psoriatic arthritis - a cross-sectional study of 246 patients from 13 countries","volume":"83","author":"Gudu","year":"2016","journal-title":"Joint Bone Spine"},{"key":"2025090312465902000_6.1.e000928.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100179"},{"key":"2025090312465902000_6.1.e000928.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205207"},{"key":"2025090312465902000_6.1.e000928.7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161330"},{"key":"2025090312465902000_6.1.e000928.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.098202"},{"key":"2025090312465902000_6.1.e000928.9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140259"},{"key":"2025090312465902000_6.1.e000928.10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5312\/wjo.v5.i4.537","article-title":"Psoriatic arthritis: epidemiology, diagnosis, and treatment","volume":"5","author":"Liu","year":"2014","journal-title":"World J Orthop"},{"key":"2025090312465902000_6.1.e000928.11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","article-title":"Quality of life in psoriatic arthritis","volume":"14","author":"Gudu","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"2025090312465902000_6.1.e000928.12","doi-asserted-by":"crossref","first-page":"839425","DOI":"10.1155\/2012\/839425","article-title":"Measuring disease activity in psoriatic arthritis","volume":"2012","author":"Wong","year":"2012","journal-title":"Int J Rheumatol"},{"key":"2025090312465902000_6.1.e000928.13","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20577"},{"key":"2025090312465902000_6.1.e000928.14","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160116"},{"key":"2025090312465902000_6.1.e000928.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210242"},{"key":"2025090312465902000_6.1.e000928.16","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000217","article-title":"Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set","volume":"2","author":"Kalyoncu","year":"2016","journal-title":"RMD Open"},{"key":"2025090312465902000_6.1.e000928.17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/34.12.1167"},{"key":"2025090312465902000_6.1.e000928.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.065763"},{"key":"2025090312465902000_6.1.e000928.19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep287"},{"key":"2025090312465902000_6.1.e000928.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"2025090312465902000_6.1.e000928.21","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"The Lancet"},{"key":"2025090312465902000_6.1.e000928.22","first-page":"789","article-title":"The dimensions of health outcomes: the health assessment questionnaire, disability, and pain scales","volume":"9","author":"Fries","year":"1982","journal-title":"J Rheumatol"},{"key":"2025090312465902000_6.1.e000928.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"2025090312465902000_6.1.e000928.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209511"},{"key":"2025090312465902000_6.1.e000928.25","first-page":"511","article-title":"Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis","volume":"24","author":"Husted","year":"1997","journal-title":"J Rheumatol"},{"key":"2025090312465902000_6.1.e000928.26","unstructured":"Maruish ME , ed. User\u2019s manual for the SF-36v2 Health Survey. 3rd edn. Lincoln, RI: QualityMetric Incorporated, 2011."},{"key":"2025090312465902000_6.1.e000928.27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131250"},{"key":"2025090312465902000_6.1.e000928.28","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.129379"},{"key":"2025090312465902000_6.1.e000928.29","unstructured":"Nunnally JC , Bernstein IH . Psychometric theory. 3rd edn. New York, NY: McGraw Hill, 1994."},{"key":"2025090312465902000_6.1.e000928.30","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131310"},{"key":"2025090312465902000_6.1.e000928.31","doi-asserted-by":"publisher","DOI":"10.1586\/erp.11.12"},{"key":"2025090312465902000_6.1.e000928.32","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110546"},{"key":"2025090312465902000_6.1.e000928.33","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"2025090312465902000_6.1.e000928.34","doi-asserted-by":"publisher","DOI":"10.1007\/s11336-008-9070-3"},{"key":"2025090312465902000_6.1.e000928.35","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1037\/0021-9010.92.2.538","article-title":"A cautionary note on the effects of range restriction on predictor intercorrelations","volume":"92","author":"Sackett","year":"2007","journal-title":"J Appl Psychol"},{"key":"2025090312465902000_6.1.e000928.36","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22256"},{"key":"2025090312465902000_6.1.e000928.37","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.057901"},{"key":"2025090312465902000_6.1.e000928.38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"2025090312465902000_6.1.e000928.39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-209055"},{"key":"2025090312465902000_6.1.e000928.40","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000806","article-title":"Tofacitinib or adalimumab versus placebo: patient-reported outcomes from opal Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"2025090312465902000_6.1.e000928.41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04308.x"},{"key":"2025090312465902000_6.1.e000928.42","first-page":"401","article-title":"Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritis","volume":"28","author":"Minnock","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312465902000_6.1.e000928.43","doi-asserted-by":"crossref","unstructured":"Cella D , Wilson H , Shalhoub H , et al . Retracted article: content validity and psychometric evaluation of functional assessment of chronic illness Therapy-Fatigue in patients with psoriatic arthritis. J Patient Rep Outcomes 2019;3.doi:10.1186\/s41687-019-0094-5","DOI":"10.1186\/s41687-019-0094-5"},{"key":"2025090312465902000_6.1.e000928.44","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181077"},{"key":"2025090312465902000_6.1.e000928.45","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40271-017-0221-4","article-title":"Important treatment outcomes for patients with psoriatic arthritis: a multisite qualitative study","volume":"10","author":"Dures","year":"2017","journal-title":"Patient"},{"key":"2025090312465902000_6.1.e000928.46","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13306"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2019-000928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:47:08Z","timestamp":1756928828000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2019-000928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,7]]},"published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1136\/rmdopen-2019-000928"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2019-000928","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}